



ImmuniD Key Technology Patents Covering ImmunTraCkeR® and ImmunIG® Granted in the United States, Europe, Canada and Japan

Grenoble, France, July 22, 2015 – ImmuniD today announced the granting of key patents in the United States, Europe, Canada and Japan. These patents cover the underlying technology of the ImmunTraCkeR® and ImmunIG® assays, which are evaluating a patient’s own immune system, both T-Cell repertoire and B-Cell repertoire. ImmunTraCkeR® has demonstrated clinical utility predicting response to immuno-oncology therapies and is currently under further validation for prediction of response and monitoring of cancer patients under treatment with immune checkpoint inhibitors.

The two patent families (WO2005056828 and WO2009095567) cover the multi-N-plex® Polymerase Chain Reaction (PCR) technology underlying the ImmunTraCkeR® and ImmunIG® assays.

“The immune system plays a fundamental role in diseases, which is why monitoring it is essential. As a pioneer in the field of immune molecular diagnostics for a decade, ImmuniD has filed multiple patent applications covering clinical applications of its immune assays in immunotherapy, cancer and infections” explained Nicolas Pasqual, Chief Scientific Officer, and Sébastien Weisbuch, Chief Operating Officer, both co-founders of ImmuniD.

"Our IP strategy focuses on ring-fencing the technology of our assays while securing the emerging clinical value. This combination creates the commercial value crucial to attract high quality investors and the funds needed to allow further validation and identification of new clinical utility for our assays," added Bernhard Sixt, ImmuniD’s Chairman and Chief Executive Officer.

About ImmuniD

ImmuniD adds precision to the immuno-oncology revolution by personalizing immunotherapy. With its decade-long experience in immune molecular diagnostics, ImmuniD provide doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmuniD’s flagship CE-marked product, ImmunTraCkeR®, evaluates the patient’s immune status based on the T lymphocyte diversity, from a simple liquid biopsy. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic assay for immune checkpoint inhibitors and other immunotherapies. In

addition, ImmunID collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies. ImmunID is ISO 9001 and ISO 13485 certified and runs a CAP-accredited laboratory in the MINATEC high-tech campus in Grenoble, France.

www.immunid.com - Follow ImmunID on Twitter: [@ImmunID](https://twitter.com/ImmunID)

Contact

Bernhard Sixt

Chairman and CEO

contact@immunid.com

Phone: +33 438 785 770